In this double-blind, cross-over, the effects of psilocybin (25mg) were assessed in healthy volunteers (n=23) who had been taking the antidepressant escitalopram (10-20mg, 14 days) or placebo before psilocybin treatment. Pretreatment with escitalopram had no relevant effect on positive mood but significantly reduced bad drug effects and adverse cardiovascular effects.
“The psychedelic psilocybin is being investigated for the treatment of depression and anxiety. Unclear is whether antidepressant treatments interact with psilocybin. The present study used a double-blind, placebo-controlled, cross-over design with two experimental test sessions to investigate the response to psilocybin (25 mg) in healthy subjects after pretreatment with escitalopram or placebo. The treatment order was random and counterbalanced. Pretreatment consisted of 10 mg escitalopram daily for 7 days, followed by 20 mg daily for 7 days, including the day of psilocybin administration, or 14 days of placebo pretreatment before psilocybin administration. Psilocybin treatments were separated by at least 16 days. The outcome measures included self-rating scales that evaluated subjective effects, autonomic effects, adverse effects, plasma brain-derived neurotrophic factor (BDNF) levels, electrocardiogram QTc time, whole-blood HTR2A and SCL6A4 gene expression, and pharmacokinetics. Escitalopram pretreatment had no relevant effect on positive mood effects of psilocybin but significantly reduced bad drug effects, anxiety, adverse cardiovascular effects, and other adverse effects of psilocybin compared with placebo pretreatment. Escitalopram did not alter the pharmacokinetics of psilocin. The half-life of psychoactive free (unconjugated) psilocin was 1.8 h (range 1.1-2.2 h), consistent with the short duration of action of psilocybin. Escitalopram did not alter HTR2A or SCL6A4 gene expression before psilocybin administration, QTc intervals, or circulating BDNF levels before or after psilocybin administration. Further studies are needed with a longer antidepressant pretreatment time and patients with psychiatric disorders to further define interactions between antidepressants and psilocybin.”
Authors: Anna M. Becker, Friederike Holze, Tanja Grandinetti, Aaron Klaiber, Vanja E. Toedtli, Karolina E. Kolaczynska, Urs Duthaler, Nimmy Varghese, Anne Eckert, Edna Grünblatt & Matthias E Liechti
Find this paper
Acute effects of psilocybin after escitalopram or placebo pretreatment in a randomized, double-blind, placebo-controlled, cross-over study in healthy subjects
Paywall | Google Scholar | Backup | 🕊
Original Placebo-Controlled Double-Blind Within-Subject Randomized
Authors associated with this publication with profiles on BlossomMatthias Liechti
Matthias Emanuel Liechti is the research group leader at the Liechti Lab at the University of Basel.
Institutes associated with this publicationUniversity of Basel
The University of Basel Department of Biomedicine hosts the Liechti Lab research group, headed by Matthias Liechti.
The psychedelics given at which dose and how many timesPsilocybin 25 mg | 1x
Linked Research Papers
Notable research papers that build on or are influenced by this paperPharmacokinetics and pharmacodynamics of oral psilocybin administration in healthy participants
This study analysed data from three clinical trials (n=79) to characterize the pharmacokinetic-pharmacodynamic relationship of orally administered psilocybin (15-30 mg). Maximal psilocin concentrations were 11 ng/ml, 17 ng/ml, and 21 ng/ml after the administration of 15, 25, and 30 mg psilocybin, respectively, and maximal levels were reached after an average of 2 hours. The duration and intensity of subjective effects were dose-dependent.
Linked Clinical TrialEffects of SERT Inhibition on the Subjective Response to Psilocybin in Healthy Subjects
The aim of the study is to investigate the effects of psilocybin after escitalopram and Placebo pretreatment. Subjective and physiological effects as well as effects on gene expression will be assessed.